Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19042193 | 0.98 | L3MBTL1 (0.46) | L3MBTL1HSD17B3HTTTHRATHRB | |
| SCHEMBL7193415 | 0.92 | ALDH1A1 (0.44) | L3MBTL1HSD17B3TDP1CES2CES1 | |
| SCHEMBL8730860 | 0.90 | TDP1 (0.46) | HTTTDP1CES2CES1ALDH1A1 | |
| SCHEMBL27944125 | 0.85 | HSD17B3 (0.62) | HSD17B3KDM4EALDH1A1LMNAESR1 | |
| SCHEMBL28209780 | 0.85 | HSD17B3 (0.62) | HSD17B3KDM4EALDH1A1LMNAESR1 | |
| SCHEMBL7197697 | 0.84 | ALDH1A1 (0.41) | L3MBTL1HSD17B3HTTTDP1CES2 | |
| SCHEMBL23891539 | 0.83 | GAA (0.54) | HSD17B3GAA | |
| SCHEMBL9419337 | 0.83 | HSD17B3 (0.43) | HSD17B3THRATHRBCES2CES1 | |
| SCHEMBL11412668 | 0.82 | CES2 (0.58) | L3MBTL1TDP1CES2CES1LMNA | |
| SCHEMBL465114 | 0.82 | CES2 (0.58) | L3MBTL1TDP1CES2CES1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960571-B2 | Silicon-based cross-coupling reagent and production method of organic compound using the same | KYOTO UNIVERSITY (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090069577-A1 | Silicon-Based Cross-Coupling Reagent and Production Method of Organic Compound Using the Same | KYOTO UNIVERSITY (JP) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069577-A1 | Silicon-Based Cross-Coupling Reagent and Production Method of Organic Compound Using the Same | DNMT1, TET3, CTCF | L3MBTL1 3155/4885HSD17B3 3146/4885HTT 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.